Mark Lees

Mark Lees has a diverse work experience in the biotechnology and healthcare industry. Mark is currently serving as the VP of Corporate Development at T-Cypher Bio since June 2021. Prior to this, they held the position of VP of Strategy and Operations at Mestag Therapeutics from June 2020 to June 2021.

Before joining Mestag Therapeutics, Mark worked as the Vice President of Operations and Corporate Strategy at F-star Biotechnology Ltd from December 2018 to June 2020. Mark also served as the Executive Operations at Immunocore Limited from January 2017 to December 2018.

Mark's previous roles include Director of Project and Portfolio Management at Magnus Life Science (May 2014-January 2017), Senior Consultant of Competitive Intelligence at Thomson Reuters (October 2012-May 2014), and Head of Business Intelligence at the National Institute for Health Research (January 2010-October 2012).

Their career started as a Consultant at Alcimed from August 2007 to August 2009. Mark Lees has extensive experience in various leadership and strategy roles within the biotechnology and healthcare industry.

Mark Lees completed their undergraduate studies from 1999 to 2003 at the University of Oxford, earning a degree in MBiochem in the field of Biochemistry. Mark then pursued further education at Saïd Business School, University of Oxford, obtaining a Master of Business Administration (MBA) degree from 2013 to 2014. Returning to their scientific interests, Mark Lees pursued a PhD from 2003 to 2007 at Imperial College London, specializing in the Genetics of autoimmune disease.